Do you want to read an article? Please log in or register.
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Cardiovascular Risk and Diseases
Related content
Heart, Artery and Coronary DiseasesTherapy and Intervention
Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study
Am Heart J.
Laursen PN, Holmvang L, Lønborg J, Køber L, Høfsten DE, Helqvist S, Clemmensen P, Kelbæk H, Jørgensen E, Lassen JF, Pedersen F, Høi-Hansen T, Therkelsen CJ, Tilsted HH, Jensen LO, Nepper-Christensen L, Sadjadieh G, Engstrøm T
doi: 10.1016/j.ahj.2018.05.018.
Heart, Artery and Coronary Diseases
Effects of Isometric Handgrip Training in Patients With Peripheral Artery Disease: A Randomized Controlled Trial
J Am Heart Assoc.
A Correia M, Oliveira PL, Farah BQ, Vianna LC, Wolosker N, Puech-Leao P, Green DJ, Cucato GG, Ritti-Dias RM
doi: 10.1161/JAHA.119.013596.
Heart, Artery and Coronary Diseases
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials
Am Heart J.
Cassese S, Ndrepepa G, Byrne RA, Laugwitz KL, Schunkert H, Fusaro M, Alfonso F, Kastrati A
doi: 10.1016/j.ahj.2019.08.020.
Heart Failure
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial
JACC Heart Fail.
McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H; VIVIDD Trial Committees and Investigators
doi: 10.1016/j.jchf.2017.08.004.
Cardiovascular Risk and Diseases
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
JAMA Cardiol
Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD
doi: 10.1001/jamacardio.2021.0660
Heart, Artery and Coronary Diseases
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Lancet.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA, THEMIS Steering Committee and Investigators.
doi: 10.1016/S0140-6736(19)31887-2.
RECOMMENDED
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
doi: 10.1016/S0140-
Heart, Artery and Coronary DiseasesHypertension
Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial.
Am Heart J.
Sherwood A, Smith PJ, Hinderliter AL, Georgiades A, Blumenthal JA
doi: 10.1016/j.ahj.2016.10.011.
Cardiovascular Risk and Diseases
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Eur Heart J.
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P
doi: 10.1093/eurheartj/ehaa082.